Comparison of the effects of dopamine D1 and D2 receptor antagonists on nerve growth factor mRNA expression

European Journal of Pharmacology

Volumn 369, Issue 1, 1999, Pages 133-143

  Ozaki, Takahiro ^a   Mui, Koji ^a   Yamagami, Sakae ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Activator protein 1; Dopamine; Neuroleptic; NGF (nerve growth factor); Schizophrenia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CYCLOHEXIMIDE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MESSENGER RNA; NERVE GROWTH FACTOR; SULPIRIDE; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE EXPRESSION; IN SITU HYBRIDIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SCHIZOPHRENIA;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENE EXPRESSION REGULATION; HALOPERIDOL; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MALE; MICE; NERVE GROWTH FACTORS; NUCLEUS ACCUMBENS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SULPIRIDE; TIME FACTORS;

EID: 0032993119     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00059-X     Document Type: Article

References (47)

1. Akbarian S., Vi-uela A., Kim J.J., Potkin S.G., Bunney W.E., Jones E.G. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch. Gen. Psychiatry. 50:1993;178-187.
2. Altsschuler L.L., Casanova M.F., Goldberg T.E., Kleinman J.E. The hippocampus parahippocampus in schizophrenic, suicide, and control brains. Arch. Gen. Psychiatry. 47:1990;1029-1034.
3. Angel P., Imagawa M., Chiu R., Stein B., Imbra R.J., Rahmsdorf H.J., Jonat C., Herrlich P., Karin M. Phorbol esteri-inducible genes contain a common cis element recognized by a PMA-modulated trans-acting factor. Cell. 49:1987;729-739.
4. Aronin N., Chase K., Sagar S.M., Sharp F.R., Difiglia M. N-Methyl-D-aspartate receptors activation in the neostriatum increases c-fos and fos-related antigens selectively in medium sized neurons. Neuroscience. 44:1991;409-420.
5. Benes F.M., Sorensen I., Bird E. Reduced neuronal size in posteriorhippocampus of schizophrenic patients. Schizophr. Bull. 17:1991;597-608.
6. Bravo R., Burkhardt J., Curran T., Muller R. Involvement of common and cell specific pathways in c-fos gene control: stable induction by cAMP in macrophages. Cell. 48:1987;251-260.
7. Bogerts B., Meertz E., Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage. Arch. Gen. Psychiatry. 42:1985;784-791.
8. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid-guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
10. Cohen R.D., Ferreira P.C.P., Gentz R., Franza Br., Curran T. The product of a fos-related gene, fra-1, binds cooperatively to the AP-1 site with Jun: transcription factor AP-1 is comprised of multiple protein complexes. Genes Dev. 3:1989;173-184.
11. Cowie A., Ivanco T.L., Fahnestock M. Mouse NGF promoter upstream sequences do not affect gene expression in mouse fibroblasts. Mol. Brain Res. 27:1994;58-62.
12. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Reyston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
13. De Groot R.P., Sassone-Corci P. Activation of Jun/AP-1 by protein kinase A. Oncogene. 7:1992;2281-2286.
14. D'Mello S.R., Heinrich G. Multiple signaling pathways interact in the regulation of nerve growth factor production in L929 fibroblasts. J. Neurochem. 57:1991;1570-1576.
15. 2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294.
16. Gwag B.J., Sessler F.M., Robine V., Springer J.E. Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat dentate gyrus. Mol. Cells. 30:1997;425-430.
17. Halazonetis T.D., Georgopoulos K., Greenberg M.E., Leder P. c-Jun dimerizes with itself and with c-Fos forming complexes of different DNA binding affinities. Cell. 55:1988;917-924.
18. Harrison P.J., Mclaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
19. Hengerer B., Lindholm D., Heumann R., Rüther U., Wagner E.F., Thoenen H. Lesion-induced increase in nerve growth factor mRNA is mediated by c-fos. Proc. Natl. Acad. Sci. U.S.A. 87:1990;3899-3903.
20. Hirai S.I., Ryseck R.P., Mechta F., Bravo R., Yaniv M. Characterization of jun D: a new member of the jun protooncogene family. EMBO J. 8:1989;1433-1439.
21. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47:1995;133-178.
22. Hughes P., Beilharz E., Gluckman P., Dragunow M. Brain-derived neurotrophic factor is induced as an immediate early gene following N-methyl-D-aspartate receptor activation. Neuroscience. 57:1993;319-328.
23. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry. 35:1994;84-95.
24. Kerwin R.W., Murray R.M. A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia. Schizophr. Res. 7:1992;1-12.
25. Kerwin R., Patel S., Meldrum B., Czudek C., Reynolds G.P. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet. 331:1988;583-584.
26. Krieckhaus E.E., Donahoe J.W., Morgan M.A. Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol. Psychiatry. 31:1992;560-570.
27. Kovelman J.A., Scheibel A.B. A neurohistological correlate of schizophrenia. Biol. Psychiatry. 19:1984;1601-1621.
28. Levi Montalcini R., Aloe L., Alleva E. A role for nerve growth factor in nervous, endocrine and immune systems. Prog. Neuroimmunol. 3:1990;1-10.
29. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and island of Calleja. Mol. Brain Res. 23:1994;21-32.
30. MacGibbon G.A., Lawlor P.A., Hughes P., Young D., Dragunow M. Differential expression of inducible transcription factors in basal ganglia neurons. Mol. Brain Res. 34:1995;294-302.
31. Mocchetti I. Theoretical basis for a pharmacology of nerve growth factor Biosynthesis. Annu. Rev. Pharmacol. Toxicol. 32:1991;303-328.
32. Mocchetti I., De Bernadi M.A., Szekelty A.M., Alho H., Brooker G., Costa E. Regulation of nerve growth factor biosynthesis by β-adrenergic receptor activation in astrocytoma cells: a potential role of c-fos protein. Proc. Natl. Acad. Sci. U.S.A. 86:1989;3891-3895.
33. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci. 14:1991;421-451.
34. Ozaki T., Katsumoto E., Yokotani N., Yamagami S. The comparative effects of Haloperidol, (-)-sulpiride, and SCH23390 on c-fos and c-jun mRNA expressions, and AP-1 DNA binding activity. Eur. Neuropsychopharmacol. 7:1997;181-187.
35. Ozaki T., Katsumoto E., Mui K., Furutsuka D., Yamagami S. Distribution of Fos- and Jun-related proteins and activator protein-1 composite factors in mouse brain induced by neuroleptics. Neuroscience. 84:1998;1187-1196.
36. Rauscher F.J., Voulalas P.J., Franza R.B., Curran T. Fos and Jun bind cooperatively to the AP-1 site: reconstitution in vitro. Genes Dev. 2:1989;1687-1699.
37. 2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience. 49:1992;285-296.
38. Ryder K., Lau L.F., Nathans D. A gene activated by growth factors is related to the oncogene v-jun. Proc. Natl. Acad. Sci. U.S.A. 85:1988;1487-1491.
39. Ryder K., Lanahan A., Perez-Albuerne E., Nathan D. Jun-D: a third messenger of the jun gene family. Proc. Natl. Acad. Sci. U.S.A. 86:1989;1500-1503.
40. Selby M.J., Edwards R., Sharp F., Rutter W.J. Mouse nerve growth factor gene: structure and expression. Mol. Cell. Biol. 7:1987;3057-3064.
41. Sherman A.D., Hegwood T.S., Baruah S., Waziri R. Deficient-mediated glutamate release from synaptosomes of schizophrenics. Biol. Psychiatry. 30:1991;1191-1198.
42. Smeal T., Angel P., Meek J., Karin M. Different requirement for formation of Jun: Jun and Jun: Fos complexes. Genes Dev. 3:1989;2091-2100.
43. 3H ]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochem. Res. 18:1993;219-223.
44. Sonnenberg J.L., Mitchelmore C., Macgregor-Leon P.F., Hempstead J., Morgan J.I., Curran T. Glutamate receptor agonists increase the expression of Fos, Fra and AP-1 DNA binding activity in the mammalian brain. J. Neurosci. Res. 24:1989;72-80.
45. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44:1987;660-669.
46. Zerial M., Toschi L., Ryseck R.P., Schuermann M., Müller R., Bravo R. The product of a novel growth factor activated gene, fosB, interacts with jun proteins, enhancing their DNA binding activity. EMBO J. 8:1989;805-813.
47. Zinn K., DiMaio D., Maniatis T. Identification of two distinct regulatory regions adjacent to the human β-interferon gene. Cell. 34:1983;865-879.